JC03 Rec'd PCT/PTO 0.9 JUN 2009

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

June 9, 2005

Date of Deposit

Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER ON/4-32823A							
TRANSMITTAL LETTER TO T	HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)							
DESIGNATED/ELECTED O	10/570200								
CONCERNING A FILING UN		10/538200							
INTERNATIONAL APPLICATION NO PCT/EP03/14747	INTERNATIONAL FILING DATE 22 December 2003 (22.12.03)	PRIORITY DATE CLAIMED 23 December 2002 (23.12.02)							
TITLE OF INVENTION	22 December 2000 (22.12.00)	20 December 2002 (23.12.02)							
EPOTHILONE DERIVATIVES									
APPLICANT(S) FOR DO/EO/US DENNI-DISCHERT ET AL.									
DENNI-DISCHERT ET AL.									
Applicant herewith submits to the United States De	esignated/Elected Office (DO/EO/US) th	ne following items and other information:							
1.   This is a FIRST submission of items cond	cerning a filing under 35 U.S.C. 371.								
☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).									
A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.									
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))									
	<ul> <li>a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. ☒ has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> </ul>								
c. is not required, as the application		g Office (RO/US).							
<ul> <li>6.  A translation of the International Application</li> <li>7.  Amendments to the claims of the International</li> </ul>		(35 U.S.C.371(c)(3)).							
	d only if not transmitted by the Internation	nal Bureau).							
<ul> <li>b.  have been transmitted by the Interest</li> <li>c.  have not been made; however, the</li> </ul>		nts has NOT expired.							
_ d. 🛛 have not been made and will not	be made.	·							
<ul> <li>8.  A translation of the amendments to the cl</li> <li>9.  An executed Declaration and Power of A</li> </ul>	ttorney (original or copy) (35 U.S.C. 371	(c)(4)).							
10. A translation of the annexes to the Internation	ational Preliminary Examination Report	under PCT Article 36 (35 U.S.C.							
371(c)(5)).									
Items 11. to 16. below concern document(s) or	information included.								
11. An Information Disclosure Statement und	er 37 CFR 1.97 and 1.98.								
12. An assignment document for recording.	A separate cover sheet in compliance w	ो vith 37 CFR 3.28 and 3.31 is included.							
13.   A FIRST preliminary amendment.									
☐ A SECOND or SUBSEQUENT preliminar	y amendment.								
14. An Application Data Sheet under 37 CFR	1.76.								
15. A substitute specification.									
16. A change of power of attorney and/or add	dress letter.								
17. A computer-readable form of the sequence	ce listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821-1.825.							
18. A second copy of the published Internation	onal Application under 35 U.S.C. 154(d)	(4).							
19. A second copy of the English language to	anslation of the International application	n under 35 U.S.C. 154(d)(4).							
20.  Other items or information:									

JC17 Rec'd PCT/PTO 09 JUN 2005

	0 / 5	<u> </u>	UU PC	T/EP03/14747			ON/4-3282	23A			
The following fe	es are su	ubmitted:							CULATIO	NS PTO USE	
								ONLY			
21. 🛭 Basi	c nationa	al fee					\$300				
22. Examination Fee											
☐ If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)											
. All other situations											
23. Search fee											
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400											
All other situations							\$				
				F 21, 22 AND 23 =				\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction											
thereof.	iieu in al	i electronic	mealum). Tr	ie iee is <b>⊅∠ou</b> for ead 	iii additioi	iai ou snee	ets of paper of	iractio	חר		
Total Sheets	Extra	sheets		each additional 50 or nd <b>up</b> to a whole nun		F	RATE				
50 - 100 =		/50 =		0		X \$	250	\$		-	
Surcharge of \$1	<b>30</b> for fu	rnishing the	e oath of decla	aration later than	⊐ 30			s			
months from the earliest claimed priority date (37 CFR 1.492(e)).						<u> </u>					
CLAIMS Total claims		20	ER FILED - 20 =	NUMBER EXTE		X \$	TE 50	\$			
Independent cla	ims	8	-3 =	<del></del>		X \$	200	\$	1,000		
MULTIPLE DEP	ENDEN	T CLAIM(S	) (if applicable	e)		+ \$	360	\$			
TOTAL OF ABOVE CALCULATIONS =							\$	1,900			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).						s					
SUBTOTAL =						\$	1,900	-			
Processing fee of \$130 for furnishing the English translation later than 30 months from the											
earliest claimed priority date (37 CFR 1.492(f)). +						\$ \$	1,900				
TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied						-	1,300				
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$					
TOTAL FEES ENCLOSED =						\$	1,900				
									mount to refunded	\$	
									charged	\$	
	k in the a	amount of \$		to cover the abo	ove fees i	s enclosed	l.				
b.  Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,900 to cover the above fees. A duplicate copy of this form is enclosed.											
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
						Jackson					
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 48,152								<u> </u>			
One Health Plaza, Building 104 (862) 778-7852											
East Ha	East Hanover, NJ 07936-1080										